Kohjin Bio rewrote its governance map on June 26. Shareholders approved amendments that move the company to a company with an audit and supervisory committee and formalise a two-person representative structure, with a representative director and chair alongside a representative director and president. The company said the switch is meant to strengthen audit and supervisory functions, enhance governance and speed decision-making through delegated authority.
A same-day board resolution then filled the two top posts. Takahito Nakamura moved from president to representative director and chair, while Yuichi Nakamura, previously senior managing director overseeing sales, became representative director and president, effective June 26. Kohjin Bio separately said the dual setup should improve operating flexibility.
Shareholders also approved a ¥10 per share dividend, or ¥51.1mn in total, effective June 29, elected four directors including the two Nakamuras, chose three directors to serve as audit and supervisory committee members, and appointed RSM Seiwa Audit Corporation as accounting auditor.
There is still a simple power fact behind the redesign. In a separate disclosure, Kohjin Bio said Takahito Nakamura remained its controlling shareholder as of March 31 with 53.91% of voting rights, made up of 43.25% held directly and 10.66% counted on an aggregated basis. The company said it had no transactions with the controlling shareholder and generally avoids such dealings.